Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michael A. Van Es, Ruben P.A. Van Eijk, Tommy M. Bunte & Leonard H. Van Den Berg. (2020) A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:7-8, pages 584-592.
Read now
Read now
Angela Genge & Benjamin Brooks. (2019) Edaravone administration in pivotal clinical Study 19. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:3-4, pages 298-299.
Read now
Read now
Articles from other publishers (13)
Varant KupelianEmma ViscidiSusan HallLi LiSusan EatonAnne DilleyNicolas Currier, Toby FergusonLaura Fanning. (2023) Increased Risk of Venous Thromboembolism in Patients With Amyotrophic Lateral Sclerosis. Neurology Clinical Practice 13:1.
Crossref
Crossref
Mengxia Gao, Lingqun Zhu, Jingling Chang, Tianyu Cao, Lianying Song, Chunli Wen, Yi Chen, Yudi Zhuo & Fei Chen. (2022) Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clinical Drug Investigation 43:1, pages 1-11.
Crossref
Crossref
Angela Genge, Benjamin Rix Brooks, Björn Oskarsson, Alexander Kalin, Ming Ji, Stephen Apple & Laura Bower. (2022) Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch. Drugs in R&D 22:3, pages 205-211.
Crossref
Crossref
Li-Qin Zhao, Ankit Parikh, Yun-Xia Xiong, Qing-Yan Ye, Ying-Guo, Xin-Fu Zhou & Hai-Yun Luo. (2022) Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats. Neurotoxicity Research 40:4, pages 995-1006.
Crossref
Crossref
Christina N. Fournier. (2022) Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 19:4, pages 1180-1192.
Crossref
Crossref
Simon Witzel, André Maier, Robert Steinbach, Julian Grosskreutz, Jan C. Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer & Albert C. Ludolph. (2022) Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology 79:2, pages 121.
Crossref
Crossref
Jonathan D. Glass & Christina N. Fournier. (2022) Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?. JAMA Neurology 79:2, pages 117.
Crossref
Crossref
Gary W. Gallagher, Dustin Nowacek, Olivia Gutgsell & Brian C. Callaghan. (2021) Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies. Muscle & Nerve 64:6, pages 641-650.
Crossref
Crossref
Emanuele D’Amico, Giuseppe Grosso, Jeri W. Nieves, Aurora Zanghì, Pam Factor-Litvak & Hiroshi Mitsumoto. (2021) Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients 13:7, pages 2273.
Crossref
Crossref
Alizée Arnoux & Luc Dupuis. 2021. 5-HT2B Receptors. 5-HT2B Receptors
367
386
.
. (2020) Sodium Phenylbutyrate–Taurursodiol for ALS. New England Journal of Medicine 383:23, pages 2293-2294.
Crossref
Crossref
John Turnbull. (2020) Reappraisal of an ALS trial: unaccounted procedural risk. The Lancet Neurology 19:9, pages 717-718.
Crossref
Crossref
Christopher J. McDermott. (2019) Clinical trials in amyotrophic lateral sclerosis. Current Opinion in Neurology 32:5, pages 758-763.
Crossref
Crossref